Similarly, the ICC subset with Beclin 1 low expression had an inferior 3-year PFS rate than ECC patient (low Beclin 1 ICC VS low Beclin ECC: 49.3% VS 50.1%, P = 0.053, Figure 4B), particularly than the Beclin 1 highly expressed ECC patients (low Beclin 1 ICC VS high Beclin ECC: 49.3% VS 72.0%, P = 0.010, Figure 4D). Here, BECN1 is linked to intrahepatic cholangiocarcinoma.